| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
4-Methoxycinnamaldehyde targets the respiratory syncytial virus (RSV) by inhibiting its cytopathic effect in infected cells. The compound may interfere with viral entry, replication, or assembly. It also modulates cellular signaling pathways involved in oxidative stress and inflammation, suggesting interactions with NF-κB, MAPK, or other stress-responsive pathways. The compound's antioxidant and anti-inflammatory activities are mediated through radical scavenging and modulation of inflammatory mediators.
|
|---|---|
| ln Vitro |
4-Methoxycinnamaldehyde effectively inhibits the cytopathic effect of RSV with an IC₅₀ of approximately 0.055 µg/mL and a selectivity index of 898.2. It exhibits antioxidant activity through radical scavenging mechanisms. The compound also shows anti-inflammatory activity by reducing the production of pro-inflammatory mediators. Antimicrobial properties have also been reported. These activities make it valuable for studying viral infections and inflammatory conditions.
|
| ln Vivo |
In vivo activity data for 4-Methoxycinnamaldehyde are limited in the literature. Based on its potent in vitro anti-RSV activity, it is anticipated to have potential in vivo efficacy in animal models of RSV infection. The compound's antioxidant and anti-inflammatory properties also suggest potential in vivo effects in models of oxidative stress and inflammation. However, specific animal studies are not extensively documented.
|
| Enzyme Assay |
The non-cellular enzyme/receptor binding assays for 4-Methoxycinnamaldehyde would typically involve antiviral activity evaluation using cell-free systems. For antioxidant activity, DPPH, ABTS, and FRAP assays can be employed to measure radical scavenging capacity. The compound's ability to inhibit viral enzymes such as viral polymerases or proteases could be assessed using enzyme inhibition assays. However, specific assays for RSV inhibition are typically cell-based.
|
| Cell Assay |
In vitro cellular assays for 4-Methoxycinnamaldehyde typically use human larynx carcinoma cell lines infected with RSV. Cells are treated with various concentrations of the compound, and the cytopathic effect is assessed microscopically or using colorimetric methods such as XTT or MTT assays. The IC₅₀ and selectivity index are calculated. Anti-inflammatory activity can be evaluated using LPS-stimulated macrophages, measuring nitric oxide and cytokine production. Antioxidant activity is assessed using cell-based ROS measurement.
|
| Animal Protocol |
In vivo animal studies for 4-Methoxycinnamaldehyde are not extensively documented. Based on its anti-RSV activity, typical study designs would involve mouse models of RSV infection. The compound would be administered orally or intranasally. Viral load in lungs, inflammatory markers, and histopathological changes would be evaluated. Efficacy would be compared to standard antiviral treatments.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 4-Methoxycinnamaldehyde are not extensively characterized. As a small lipophilic aldehyde (molecular weight 162.19), it is expected to have good oral absorption and membrane permeability. Metabolic pathways likely involve oxidation of the aldehyde group to the corresponding carboxylic acid, as well as phase II conjugation. The compound may undergo extensive first-pass metabolism. Specific PK parameters such as half-life, Cmax, and bioavailability are not well documented.
|
| Toxicity/Toxicokinetics |
Toxicological data for 4-Methoxycinnamaldehyde are limited. As a naturally occurring cinnamaldehyde derivative, it is generally considered to have moderate toxicity at high concentrations. Skin and eye irritation may occur upon contact. The compound may cause allergic reactions in sensitive individuals. Comprehensive toxicology studies are not available. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
3-(4-Methoxyphenyl)-2-propenal is one of the cinnamaldehyde compounds. It has been reported that 4-methoxycinnamal exists in Pogostemon cablin and Artemisia annua, and relevant data are available for reference.
4-Methoxycinnamaldehyde is a research-grade natural product intended for laboratory use only. It is not approved for clinical use as a therapeutic agent. Its primary applications include studying antiviral mechanisms against RSV, investigating antioxidant and anti-inflammatory activities, and serving as a reference standard for the analysis of cinnamaldehyde derivatives. It is also used in structure-activity relationship studies of para-substituted cinnamaldehyde analogs. |
| Molecular Formula |
C10H10O2
|
|---|---|
| Molecular Weight |
162.1852
|
| Exact Mass |
162.068
|
| CAS # |
1963-36-6
|
| PubChem CID |
641294
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
308.7±17.0 °C at 760 mmHg
|
| Melting Point |
55-60ºC(lit.)
|
| Flash Point |
146.5±14.5 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.559
|
| LogP |
2.07
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
12
|
| Complexity |
155
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC=C(C=C1)/C=C/C=O
|
| InChi Key |
AXCXHFKZHDEKTP-NSCUHMNNSA-N
|
| InChi Code |
InChI=1S/C10H10O2/c1-12-10-6-4-9(5-7-10)3-2-8-11/h2-8H,1H3/b3-2+
|
| Chemical Name |
(E)-3-(4-methoxyphenyl)prop-2-enal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1656 mL | 30.8280 mL | 61.6561 mL | |
| 5 mM | 1.2331 mL | 6.1656 mL | 12.3312 mL | |
| 10 mM | 0.6166 mL | 3.0828 mL | 6.1656 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
